Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 0.24% Ophthalmic Solution Used Twice Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)

Trial Profile

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 0.24% Ophthalmic Solution Used Twice Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetirizine (Primary)
  • Indications Allergic conjunctivitis
  • Focus Adverse reactions; Registrational
  • Sponsors Aciex Therapeutics
  • Most Recent Events

    • 11 Apr 2017 According to Nicox media release, A Prescription Drug User Fee Act (PDUFA) date of September 8, 2017 was assigned by the US FDA for its decision on the revised NDA for ZERVIATE(cetirizine ophthalmic solution) for the treatment of ocular itching associated with allergic conjunctivitis, and revised NDA was submitted on March 8, 2017.
    • 21 Jun 2016 According to Nicox media release, the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for AC-170, a novel, proprietary, cetirizine eye drop formulation, for the treatment of ocular itching associated with allergic conjunctivitis. The FDA also granted Priority Review and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 18, 2016.
    • 19 Apr 2016 According to a Nicox media release, the company has submitted an NDA for AC-170 (cetirizine eye drop formulation) for the treatment of ocular itching associated with allergic conjunctivitis. The company also requested a Priority Review, which, if obtained, could result in an FDA decision by the end of 2016 based on Prescription Drug User Fee Act (PDUFA) performance goals.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top